Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81 Leukemia 41 Gastrointestinal Stromal Tumors 32 Precursor Cell Lymphoblastic Leukemia-Lymphoma 30 Leukemia, Myeloid, Chronic-Phase 27 Blast Crisis 13 Neoplasms 10 Neoplasm Metastasis 10 Melanoma 10 Brain Neoplasms 10 Lung Neoplasms 9 Prostatic Neoplasms 8 Leukemia, Myeloid, Acute 8 Gliosarcoma 8 Glioblastoma 8 Leukemia, Myeloid, Accelerated Phase 7 Glioma 6 Carcinoma, Non-Small-Cell Lung 6 Sarcoma 5 Philadelphia Chromosome 5 Oligodendroglioma 5 Recurrence 4 Primary Myelofibrosis 4 Polycythemia Vera 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Head and Neck Neoplasms 4 Central Nervous System Neoplasms 4 Breast Neoplasms 4 Astrocytoma 4

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumor × Imatinib Mesylate × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡